Anita R Peoples1, Joseph A Roscoe2, Robert C Block3, Charles E Heckler2, Julie L Ryan4, Karen M Mustian2, Michelle C Janelsins2, Luke J Peppone2, Dennis F Moore5, Charlotte Coles6, Karen L Hoelzer7, Gary R Morrow2, Ann M Dozier3. 1. Department of Surgery, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA. Anita_Peoples@urmc.rochester.edu. 2. Department of Surgery, University of Rochester Medical Center, 265 Crittenden Blvd., CU 420658, Rochester, NY, 14642, USA. 3. Department of Public Health Sciences, University of Rochester Medical Center, 265 Crittenden Blvd., Rochester, NY, 14642, USA. 4. Department of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY, 14642, USA. 5. Wichita NCORP, Wichita, KS, USA. 6. Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, MN, USA. 7. Heartland Cancer Research NCORP, Decatur, IL, USA.
Abstract
PURPOSE: Cancer-related fatigue (CRF) is a prevalent and distressing side effect of cancer and its treatment that remains inadequately understood and poorly managed. A better understanding of the factors contributing to CRF could result in more effective strategies for the prevention and treatment of CRF. The objectives of this study were to examine the prevalence, severity, and potential predictors for the early onset of CRF after chemotherapy cycle 1 in breast cancer patients. METHODS: We report on a secondary data analysis of 548 female breast cancer patients from a phase III multi-center randomized controlled trial examining antiemetic efficacy. CRF was assessed by the Brief Fatigue Inventory at pre- and post-chemotherapy cycle 1 as well as by the four-day diary. RESULTS: The prevalence of clinically relevant post-CRF was 75%. Linear regression showed that pre-treatment CRF, greater nausea, disturbed sleep, and younger age were significant risk factors for post-CRF (adjusted R2 = 0.39; P < 0.0001). Path modeling showed that nausea severity influenced post-CRF both directly and indirectly by influencing disturbed sleep. Similarly, pre-treatment CRF influenced post-CRF directly as well as indirectly through both nausea severity and disturbed sleep. Pearson correlations showed that changes in CRF over time were significantly correlated with concurrent changes in nausea severity (r = 0.41; P < 0.0001) and in disturbed sleep (r = 0.20; P < 0.0001). CONCLUSION: This study showed a high prevalence (75%) of clinically relevant CRF in breast cancer patients following their initial chemotherapy, and that nausea severity, disturbed sleep, pre-treatment CRF, and age were significant predictors of symptom.
RCT Entities:
PURPOSE:Cancer-related fatigue (CRF) is a prevalent and distressing side effect of cancer and its treatment that remains inadequately understood and poorly managed. A better understanding of the factors contributing to CRF could result in more effective strategies for the prevention and treatment of CRF. The objectives of this study were to examine the prevalence, severity, and potential predictors for the early onset of CRF after chemotherapy cycle 1 in breast cancerpatients. METHODS: We report on a secondary data analysis of 548 female breast cancerpatients from a phase III multi-center randomized controlled trial examining antiemetic efficacy. CRF was assessed by the Brief Fatigue Inventory at pre- and post-chemotherapy cycle 1 as well as by the four-day diary. RESULTS: The prevalence of clinically relevant post-CRF was 75%. Linear regression showed that pre-treatment CRF, greater nausea, disturbed sleep, and younger age were significant risk factors for post-CRF (adjusted R2 = 0.39; P < 0.0001). Path modeling showed that nausea severity influenced post-CRF both directly and indirectly by influencing disturbed sleep. Similarly, pre-treatment CRF influenced post-CRF directly as well as indirectly through both nausea severity and disturbed sleep. Pearson correlations showed that changes in CRF over time were significantly correlated with concurrent changes in nausea severity (r = 0.41; P < 0.0001) and in disturbed sleep (r = 0.20; P < 0.0001). CONCLUSION: This study showed a high prevalence (75%) of clinically relevant CRF in breast cancerpatients following their initial chemotherapy, and that nausea severity, disturbed sleep, pre-treatment CRF, and age were significant predictors of symptom.
Entities:
Keywords:
Breast cancer; Cancer-related fatigue; Disturbed sleep; Nausea
Authors: Mogens Groenvold; Morten Aagaard Petersen; Ellen Idler; Jakob Bue Bjorner; Peter M Fayers; Henning T Mouridsen Journal: Breast Cancer Res Treat Date: 2007-01-03 Impact factor: 4.872
Authors: Michael A Andrykowski; John E Schmidt; John M Salsman; Abbie O Beacham; Paul B Jacobsen Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Julia E Inglis; Michelle C Janelsins; Eva Culakova; Karen M Mustian; Po-Ju Lin; Ian R Kleckner; Luke J Peppone Journal: Support Care Cancer Date: 2019-07-02 Impact factor: 3.603
Authors: Komal Singh; Steven M Paul; Kord M Kober; Yvette P Conley; Fay Wright; Jon D Levine; Paule V Joseph; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-11-02 Impact factor: 3.612
Authors: Julia E Inglis; Po-Ju Lin; Sarah L Kerns; Ian R Kleckner; Amber S Kleckner; Daniel A Castillo; Karen M Mustian; Luke J Peppone Journal: Nutr Cancer Date: 2019-01-26 Impact factor: 2.900
Authors: Fay Wright; Bruce A Cooper; Yvette P Conley; Marilyn J Hammer; Lee-May Chen; Steven M Paul; Jon D Levine; Christine Miaskowski; Kord M Kober Journal: Fatigue Date: 2017-05-18
Authors: Julia E Inglis; Amber S Kleckner; Po-Ju Lin; Nikesha J Gilmore; Eva Culakova; Amy C VanderWoude; Karen M Mustian; I Diana Fernandez; Richard F Dunne; Jeremy Deutsch; Luke J Peppone Journal: Nutr Cancer Date: 2020-08-19 Impact factor: 2.900
Authors: Susan Grayson; Susan Sereika; Caroline Harpel; Emilia Diego; Jennifer G Steiman; Priscilla F McAuliffe; Susan Wesmiller Journal: Support Care Cancer Date: 2021-07-10 Impact factor: 3.603
Authors: Laura B Oswald; Kelly A Hyland; Sarah L Eisel; Aasha I Hoogland; Hans Knoop; Ashley M Nelson; Javier Pinilla-Ibarz; Kendra Sweet; Paul B Jacobsen; Heather S L Jim Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.359